A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

Running, not enrolling · Not applicable

Conditions studied: Rheumatoid Arthritis, Inflammatory Disease

In brief

This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.

Key facts

Study ID

NCT06513507

Run by

Raphael Pharma

People needed

12

Starts

2024-06-03

Expected to finish

2024-12-31

Last updated by the study team

2024-11-21

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, over 25 years of age
• Positive anti-CCP blood test
• Active RA-related inflammation with at least 2 swollen joints
• University graduate
• Generally healthy with no uncontrolled chronic disease
• Able to read, understand, and sign informed consent
• Resides in the USA
• Willing to comply with study requirements and avoid other cannabis products during the study period

You may not qualify if…

• Pre-existing chronic conditions preventing adherence
• Severe allergic reactions requiring an Epi-pen
• Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
• Pregnant or breastfeeding women
• Recent invasive medical procedure or surgery
• Active malignancy or ongoing oncology treatment
• Use of cytochrome P450 or 3A4 inhibitors
• History of substance abuse

Where it is running

• Citruslabs — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.